Search

Your search keyword '"Ueki, Y."' showing total 1,107 results
Start Over Author "Ueki, Y."
1,107 results on '"Ueki, Y."'

3. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study

Author

Michitsuji, T, primary, Fukui, S, additional, Morimoto, S, additional, Endo, Y, additional, Nishino, A, additional, Nishihata, S, additional, Tsuji, Y, additional, Shimizu, T, additional, Umeda, M, additional, Sumiyoshi, R, additional, Koga, T, additional, Iwamoto, N, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Ohtsubo, H, additional, Takaoka, H, additional, Hamada, H, additional, Tsuru, T, additional, Nawata, M, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, Kawakami, A, additional, and Kawashiri, S-Y, additional

Published
2023
Full Text
View/download PDF

4. Effect of alirocumab on quantitative flow ratio and diameter stenosis in non-infarct related arteries from patients with acute myocardial infarction: a PACMAN-AMI randomized clinical trial substudy

Author

Baer, S, primary, Kavaliauskaite, R, additional, Otsuka, T, additional, Ueki, Y, additional, Haener, J, additional, Siontis, G C M, additional, Van Geuns, R, additional, Daemen, J, additional, Spirk, D, additional, Engstrom, T, additional, Lang, I, additional, Windecker, S, additional, Koskinas, K C, additional, Losdat, S, additional, and Raeber, L, additional

Published
2023
Full Text
View/download PDF

5. Long-term prognostic risk score for CLTI including nutritional state

Author

Okina, Y, primary, Ueki, Y, additional, Kato, T, additional, Miura, T, additional, Oyama, Y, additional, Hashizume, N, additional, Yokota, D, additional, Taki, M, additional, Senda, K, additional, Okina, Y, additional, Wakabyashi, T, additional, Fujimori, K, additional, Karube, K, additional, Sakai, T, additional, and Kuwahara, K, additional

Published
2023
Full Text
View/download PDF

6. Frequency, predictors and clinical outcomes of AMI patients with triple regression of coronary atherosclerosis: A sub-analysis of the PACMAN AMI trial

Author

Biccire, F G, primary, Haner, J, additional, Ueki, Y, additional, Shibutani, H, additional, Otsuka, T, additional, Hofbauer, T M, additional, Van Jeuns, R J, additional, Spirk, D, additional, Daemen, J, additional, Iglesias, J, additional, Windecker, S, additional, Engstrom, T, additional, Lang, I, additional, Koskinas, K C, additional, and Raber, L, additional

Published
2023
Full Text
View/download PDF

7. Association between quantitative flow ratio and non-target-vessel-related events before planned staged percutaneous coronary intervention in patients with acute coronary syndrome

Author

Baer, S, primary, Kavaliauskaite, R, additional, Otsuka, T, additional, Ueki, Y, additional, Haener, J D, additional, Siontis, G C M, additional, Lanz, J, additional, Praz, F, additional, Pilgrim, T, additional, Stortecky, S, additional, Losdat, S, additional, Windecker, S, additional, and Raeber, L, additional

Published
2023
Full Text
View/download PDF

8. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study.

Author

Michitsuji, T, Fukui, S, Morimoto, S, Endo, Y, Nishino, A, Nishihata, S, Tsuji, Y, Shimizu, T, Umeda, M, Sumiyoshi, R, Koga, T, Iwamoto, N, Origuchi, T, Ueki, Y, Yoshitama, T, Eiraku, N, Matsuoka, N, Okada, A, Fujikawa, K, and Ohtsubo, H

Subjects
ULTRASONIC imaging, COHORT analysis, JAPANESE people, RHEUMATOID arthritis, DISEASE duration, ANTIRHEUMATIC agents
Abstract

Objective: The optimal strategy for difficult-to-treat (D2T) rheumatoid arthritis (RA) has not been identified, and the ultrasound characteristics of D2T RA have not been reported. We investigated the clinical characteristics and factors contributing to the outcome in D2T RA in a multicentre RA ultrasound observational cohort. Method: We reviewed 307 Japanese patients diagnosed with RA who underwent treatment with biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). We compared the differences in patient characteristics between the D2T RA and non-D2T RA groups. We examined the factors contributing to a good response [defined as b/tsDMARD continuation and Clinical Disease Activity Index (CDAI) ≤ 10 at 12 months] in the D2T RA patient group. Results: Forty-three patients (14%) were categorized as D2T RA and the remaining 264 (86%) as non-D2T RA at baseline. The grey-scale (GS) score, disease duration, and CDAI at the initiation of treatment were significantly higher in the D2T RA group than in the non-D2T RA group. In contrast, the power Doppler (PD) score was not significantly different between the two groups. Of the 43 D2T RA patients, 20 achieved a good response. The introduction of CTLA4-Ig (n = 5) was significantly associated with a good response in analysis based on inverse probability weighting with propensity score. GS and PD scores at baseline were not significantly associated with therapeutic response at 12 months in D2T RA patients. Conclusions: Patients with D2T RA had high clinical and ultrasound activity and poor responses to treatment with b/tsDMARDs. CTLA4-Ig was associated with a good response at 12 months in D2T RA patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus.

Author

Ueki, Y, Goldfarb, IS, Harindranath, N, Gore, M, Koprowski, H, Notkins, AL, and Casali, P

Subjects
Biomedical and Clinical Sciences, Immunology, Biodefense, Infectious Diseases, Vaccine Related, Prevention, Biotechnology, Immunization, Good Health and Well Being, Antibodies, Monoclonal, Antibody Formation, Antibody-Producing Cells, B-Lymphocytes, Cells, Cultured, Clone Cells, Genes, Immunoglobulin, Herpesvirus 4, Human, Humans, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Immunoglobulin Variable Region, Immunoglobulins, Kinetics, Rabies virus, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

We quantitated and characterized the changes in the human B cell repertoire, at the clonal level, before and after immunization with rabies virus. Moreover, we generated 10 monoclonal cell lines producing IgM, IgG, and IgA antibodies to the virus. We found that in healthy subjects, not previously exposed to the virus, nearly 2% of the circulating B lymphocytes were committed to the production of antibodies that bound the virus. These B cells expressed the surface CD5 molecule. The antibodies they produced were polyreactive IgM that displayed a relatively low affinity for the virus components (Kd, 1.0-2.4 x 10(-6) g/microliters). After immunization, different anti-virus (IgG and IgA) antibody-producing cells consistently appeared in the circulation and increased from less than 0.005% to greater than 10% of the total B cells committed to the production of IgG and IgA, respectively. Most of such B cells do not express CD5 and produce monoreactive antibodies of high affinity for rabies virus (Kd, 6.5 x 10(-9) to 1.2 x 10(-10) g/microliters). One of these IgG mAbs efficiently neutralized rabies virus in vitro and in vivo, as detailed elsewhere (Dietzschold, B., P. Casali, Y. Ueki, M. Gore, C. E. Rupprecht, A. L. Notkins, and H. Koprowski, manuscript submitted for publication). Hybridization experiments using probes specific for the different human V gene segment families revealed that cell precursors producing low affinity IgM binding to rabies virus utilized a restricted number of VH gene segments (i.e., only members of the VHIIIb subfamily), whereas cell precursors producing high affinity IgG and IgA to rabies virus utilized an assortment of different VH gene segments (i.e., members of the VHI, VHIII, VHIV, and VHVI families and VHIIIb subfamily). In conclusion, our studies show that EBV transformation in conjunction with limiting dilution technology and somatic cell hybridization techniques are useful methods for quantitating, at the B cell clonal level, the human antibody response to foreign Ags and for generating human mAbs of predetermined specificity and high affinity.

Published
1990

13. Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: insights from the PACMAN-AMI randomized trial

Author

Koskinas, K C, primary, Losdat, S, additional, Shibutani, H, additional, Ueki, Y, additional, Otsuka, T, additional, Haener, J, additional, Fahrni, G, additional, Iglesias, J F, additional, Spirk, D, additional, Van Geuns, R J, additional, Daemen, J, additional, Windecker, S, additional, Engstrom, T, additional, Lang, I, additional, and Raber, L, additional

Published
2022
Full Text
View/download PDF

14. Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial

Author

Ueki, Y, primary, Haner, J, additional, Losdat, S, additional, Gargiulo, G, additional, Bar, S, additional, Otsuka, T, additional, Kavaliauskaite, R, additional, Mitter, V, additional, Temperli, F, additional, Shibutani, H, additional, Siontis, G, additional, Valgimigli, M, additional, Windecker, S, additional, Koskinas, K, additional, and Raber, L, additional

Published
2022
Full Text
View/download PDF

16. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial

Author

Räber, L., Ueki, Y., Otsuka, T., Losdat, S., Häner, J.D., Lonborg, J., Fahrni, G., Iglesias, J.F., Geuns, R.J.M. van, Ondracek, A.S., Jensen, M.D., Zanchin, C., Stortecky, S., Spirk, D., Siontis, G.C.M., Saleh, L., Matter, C.M., Daemen, J., Mach, F., Heg, D., Windecker, S., Engstrøm, T., Lang, I.M., Koskinas, K.C., Räber, L., Ueki, Y., Otsuka, T., Losdat, S., Häner, J.D., Lonborg, J., Fahrni, G., Iglesias, J.F., Geuns, R.J.M. van, Ondracek, A.S., Jensen, M.D., Zanchin, C., Stortecky, S., Spirk, D., Siontis, G.C.M., Saleh, L., Matter, C.M., Daemen, J., Mach, F., Heg, D., Windecker, S., Engstrøm, T., Lang, I.M., and Koskinas, K.C.

Abstract

Item does not contain fulltext, IMPORTANCE: Coronary plaques that are prone to rupture and cause adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown. OBJECTIVE: To determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction. DESIGN, SETTING, AND PARTICIPANTS: The PACMAN-AMI double-blind, placebo-controlled, randomized clinical trial (enrollment: May 9, 2017, through October 7, 2020; final follow-up: October 13, 2021) enrolled 300 patients undergoing percutaneous coronary intervention for acute myocardial infarction at 9 academic European hospitals. INTERVENTIONS: Patients were randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initiated less than 24 hours after urgent percutaneous coronary intervention of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin, 20 mg). MAIN OUTCOMES AND MEASURES: Intravascular ultrasonography (IVUS), near-infrared spectroscopy, and optical coherence tomography were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume from baseline to week 52. Two powered secondary end points were changes in near-infrared spectroscopy-derived maximum lipid core burden index within 4 mm (higher values indicating greater lipid content) and optical coherence tomography-derived minimal fibrous cap thickness (smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52. RESULTS: Among 300 randomized patients (mean [SD] age, 58.5 [9.7] years; 56 [18.7%] women; mean [SD] low

Published
2022

18. Frequency and prognostic impact of periprocedural myocardial infarction determined by various MI definitions in patients with chronic coronary syndromes undergoing percutaneous coronary intervention

Author

Ueki, Y., Otsuka, T., Bar, S., Koskinas, K., Losdat, S., Heg, D., Zanchin, T., Siontis, G., Praz, F., Haner, J., Susuri, N., Stortecky, S., Thomas Pilgrim, Windecker, S., and Raber, L.

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Background Several definitions of peri-procedural myocardial infarction (MI) requiring different biomarker thresholds with or without ancillary criteria for myocardial ischemia are currently recommended without being fully validated in real-world patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). Objectives We aimed to evaluate the prevalence and prognostic value of high-sensitivity cardiac troponin-based peri-procedural MI according to contemporary MI definitions using a large real-world PCI cohort. Methods In CCS patients undergoing elective PCI enrolled to the Bern PCI registry (NCT02241291) between 2010 and 2018, peri-procedural myocardial injury and infarction were assessed according to the 4th and 3rd universal definition of MI (UDMI), academic research consortium (ARC)-2, and Society for Cardiovascular Angiography and Interventions (SCAI) criteria. The primary endpoint was cardiac death at 1 year. Results Among 4404 CCS patients, peri-procedural MI defined by the 4th UDMI, 3rd UDMI, ARC-2, and SCAI were observed in 14.9%, 18.0%, 2.0%, and 2.0% of patients, respectively. Cardiac mortality at 1 year in patients with peri-procedural MI defined by 4th UDMI, 3rd UDMI, ARC-2, and SCAI were 3.0%, 2.9%, 5.8%, and 10.0%, respectively. After multivariate adjustments, peri-procedural MI defined by the ARC-2 and SCAI were independently associated with cardiac death at 1 year, while those defined by the 4th and 3rd UDMI were not. Conclusion Among CCS patients undergoing PCI, periprocedural MIs defined by theARC-2 and SCAI occurred 7 to 9 times less frequently as compared with the 4th and 3rd UDMI, and were the only definitions significantly associated with cardiac mortality. Funding Acknowledgement Type of funding sources: None. Cardiac death at 1 year

Published
2021
Full Text
View/download PDF

26. Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan

Author

Endo, Y, primary, Kawashiri, S-Y, additional, Nishino, A, additional, Michitsuji, T, additional, Tomokawa, T, additional, Nishihata, S, additional, Okamoto, M, additional, Tsuji, Y, additional, Tsuji, S, additional, Shimizu, T, additional, Sumiyoshi, R, additional, Igawa, T, additional, Koga, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Otsubo, H, additional, Takaoka, H, additional, Hamada, H, additional, Tsuru, T, additional, Nawata, M, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, and Kawakami, A, additional

Published
2021
Full Text
View/download PDF

28. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial

Author

Zanchin, C., Koskinas, K.C., Ueki, Y., Losdat, S., Häner, J.D., Bär, S., Otsuka, T., Inderkum, A., Jensen, M.R.J., Lonborg, J., Fahrni, G., Ondracek, A.S., Daemen, J., Geuns, R.J.M. van, Iglesias, J.F., Matter, C.M., Spirk, D., Juni, P., Mach, F., Heg, D., Engstrom, T., Lang, I., Windecker, S., Räber, L., Zanchin, C., Koskinas, K.C., Ueki, Y., Losdat, S., Häner, J.D., Bär, S., Otsuka, T., Inderkum, A., Jensen, M.R.J., Lonborg, J., Fahrni, G., Ondracek, A.S., Daemen, J., Geuns, R.J.M. van, Iglesias, J.F., Matter, C.M., Spirk, D., Juni, P., Mach, F., Heg, D., Engstrom, T., Lang, I., Windecker, S., and Räber, L.

Abstract

Contains fulltext : 235282.pdf (Publisher’s version ) (Closed access), BACKGROUND: The risk for cardiovascular adverse events after acute myocardial infarction (AMI) remains high despite potent medical treatment including low-density lipoprotein cholesterol (LDL-C) lowering with statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies substantially reduce LDL-C when added to statin. Alirocumab, a monoclonal antibody to PCSK9, reduces major adverse cardiovascular events after AMI. The effects of alirocumab on coronary atherosclerosis including plaque burden, plaque composition and fibrous cap thickness in patients presenting with AMI remains unknown. AIMS: To determine the effect of LDL-C lowering with alirocumab on top of high-intensity statin therapy on intravascular ultrasound (IVUS)-derived percent atheroma volume (PAV), near-infrared spectroscopy (NIRS)-derived maximum lipid core burden index within 4 mm (maxLCBI(4 mm)) and optical coherence tomography (OCT)-derived fibrous cap thickness (FCT) in patients with AMI. METHODS: In this multicenter, double-blind, placebo-controlled trial, 300 patients with AMI (ST-elevation or non-ST-elevation myocardial infarction) were randomly assigned to receive either biweekly subcutaneous alirocumab (150 mg) or placebo beginning <24 hours after the acute event as add-on therapy to rosuvastatin 20 mg. Patients undergo serial IVUS, NIRS and OCT in the two non-infarct related arteries at baseline (at the time of treatment of the culprit lesion) and at 52 weeks. The primary endpoint, change in IVUS-derived PAV, and the powered secondary endpoints, change in NIRS-derived maxLCBI(4 mm), and OCT-derived minimal FCT, will be assessed 52 weeks post randomization. SUMMARY: The PACMAN-AMI trial will determine the effect of alirocumab on top of high-intensity statin therapy on high-risk coronary plaque characteristics as assessed by serial, multimodality intracoronary imaging in patients presenting with AMI. CLINICAL TRIAL REGISTRATION: NCT03067844.

Published
2021

31. Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan.

Author

Endo, Y, Kawashiri, S-Y, Nishino, A, Michitsuji, T, Tomokawa, T, Nishihata, S, Okamoto, M, Tsuji, Y, Tsuji, S, Shimizu, T, Sumiyoshi, R, Igawa, T, Koga, T, Iwamoto, N, Ichinose, K, Tamai, M, Nakamura, H, Origuchi, T, Ueki, Y, and Yoshitama, T

Subjects
LONGITUDINAL method, COHORT analysis, JAPANESE people, RHEUMATOID arthritis, ULTRASONIC imaging, TREATMENT effectiveness
Abstract

This study investigated the effectiveness of treatment with Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA) assessed by ultrasonography (US) activity, and the influence of patient characteristics and previous treatments. This prospective study assessed 60 treatment initiations among 53 Japanese patients diagnosed with RA who underwent treatment with JAK inhibitors during June 2013 to February 2020. Of the 53 patients, seven patients were enrolled in duplicate because they were treated with two different JAK inhibitors at different periods. For each case, the improvement rate on the power Doppler (PD) score was assessed at 6 month follow-up. Median improvement rate of PD score was used to classify cases as either US responders or non-responders, and patient characteristics were compared between the two groups. All indicators of clinical disease activity and US activity showed a significant improvement at 3 months compared with baseline. Although the JAK inhibitor-cycler group and the interleukin-6 (IL-6) inhibitor inadequate response (IR) group tended to show a later improvement for US activity, all indicators of clinical disease activity and US activity showed a significant improvement at 6 months compared with baseline for both groups. Multivariate analysis showed that concomitant methotrexate use and an IR to the previous biologic or targeted-synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) treatment were independently and significantly associated with US responders. Use of a JAK inhibitor in combination with methotrexate and an absence of IR to any previous b/tsDMARDs demonstrated superior effectiveness for patients with RA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Randomized comparison of optical coherence tomography versus angiography to guide Bioresorbable vascular scaffold implantation: The OPTICO BVS study

Author

Ueki, Y., Yamaji, K., Barbato, E., Nef, H., Brugaletta, S., Fasano, Alfonso, Hill, J., Cook, S., Burzotta, Francesco, Karagiannis, A., Windecker, S., Raber, L., Alfonso F., Burzotta F. (ORCID:0000-0002-6569-9401), Ueki, Y., Yamaji, K., Barbato, E., Nef, H., Brugaletta, S., Fasano, Alfonso, Hill, J., Cook, S., Burzotta, Francesco, Karagiannis, A., Windecker, S., Raber, L., Alfonso F., and Burzotta F. (ORCID:0000-0002-6569-9401)

Abstract

Purpose: We investigated whether optical coherence tomography (OCT)-guided bioresorbable vascular scaffolds (BVS) implantation can improve in-scaffold minimal lumen area (MLA) at 6-month compared with angiography guidance. Methods: The OPTICO BVS was a randomized, international multicenter, assessor blind, superiority trial comparing OCT- versus angiography-guided percutaneous coronary intervention (PCI) (1:1 allocation) in patients with coronary artery disease undergoing Absorb BVS 1.1 implantation. The primary endpoint was in-scaffold MLA at 6-month. Results: The trial was prematurely stopped on May 31, 2017 after enrollment of 38 of 270 planned patients (14%) following the retraction of the device in Europe. Patients were randomly assigned to OCT- (n = 19) or angiography-guided PCI (n = 19). Scaffold diameter (OCT 3.0 ± 0.3 mm vs. angiography 3.1 ± 0.3 mm, P =.333) and length (28.8 ± 13.6 mm vs. 23.8 ± 12.3 mm, P =.223) were comparable. There was no significant difference in in-scaffold MLA at 6 months (4.47mm2 vs. 5.08mm2, P =.692). Scaffold expansion at 6-month was significantly higher in the OCT-guided PCI as compared with angiography-guided PCI (84.5% vs. 76.5%, P =.010). There was no significant difference in clinical outcomes. Conclusions: Although in-scaffold MLA at 6-month did not differ between groups, scaffold expansion was improved following OCT- as compared with angiography-guided PCI. The findings of this study must be interpreted in view of the premature termination with inclusion of 14% of the initially planned study sample.

Published
2020

34. Discrepancy between clinical and ultrasound remissions in rheumatoid arthritis: a multicentre ultrasound cohort study in Japan

Author

Endo, Y, primary, Kawashiri, S-Y, additional, Nishino, A, additional, Okamoto, M, additional, Tsuji, S, additional, Shimizu, T, additional, Sumiyoshi, R, additional, Igawa, T, additional, Koga, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Otsubo, H, additional, Takaoka, H, additional, Hamada, H, additional, Tsuru, T, additional, Nagano, S, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, and Kawakami, A, additional

Published
2021
Full Text
View/download PDF

44. Prognostic value of intracoronary imaging-derived measures for non-infarct related vessel revascularization throughout 7 years among patients with ST-elevation myocardial infarction

Author

Ueki, Y, primary, Karagiannis, A, additional, Bar, S, additional, Yamaji, K, additional, Taniwaki, M, additional, Roffi, M, additional, Holmvang, L, additional, Maldonado, R, additional, Pedrazzini, G, additional, Kelbaek, H, additional, Radu, M, additional, Windecker, S, additional, and Raber, L, additional

Published
2020
Full Text
View/download PDF

46. Quantitative flow ratio to predict non-target-vessel-related events at 5 years in STEMI patients undergoing angiography-guided revascularization

Author

Baer, S, primary, Kavaliauskaite, R, additional, Ueki, Y, additional, Otsuka, T, additional, Engstrom, T, additional, Baumbach, A, additional, Roffi, M, additional, Von Birgelen, C, additional, Vukcevic, V, additional, Pedrazzini, G, additional, Kornowski, R, additional, Tueller, D, additional, Losdat, S, additional, Windecker, S, additional, and Raeber, L, additional

Published
2020
Full Text
View/download PDF

48. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study

Author

Endo, Y, primary, Koga, T, additional, Kawashiri, S-y, additional, Morimoto, S, additional, Nishino, A, additional, Okamoto, M, additional, Tsuji, S, additional, Takatani, A, additional, Shimizu, T, additional, Sumiyoshi, R, additional, Igawa, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Hamada, H, additional, Tsuru, T, additional, Nagano, S, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, and Kawakami, A, additional

Published
2020
Full Text
View/download PDF

50. FRI0098 ASSOCIATION BETWEEN THE SEROLOGIC STATUS OF ISOTYPE-SPECIFIC AUTOANTIBODIES AND THERAPEUTIC EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT: A PROSPECTIVE ULTRASOUND COHORT STUDY IN JAPAN

Author

Kawashiri, S. Y., primary, Endo, Y., additional, Nishino, A., additional, Shimizu, T., additional, Ueki, Y., additional, Eiraku, N., additional, Okada, A., additional, Matsuoka, N., additional, Yoshitama, T., additional, Nakamura, H., additional, Tamai, M., additional, Origuchi, T., additional, Toes, R., additional, Huizinga, T., additional, and Kawakami, A., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results